3-methyl-1-propyl-pyrrolidine-2,5-dione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-methyl-1-propyl-pyrrolidine-2,5-dione
• 英文别名: 3-Methyl-1-propyl-pyrrolidin-2,5-dion；3-Methyl-1-propylpyrrolidine-2,5-dione
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: STRMSTHRCSNSNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 3-methyl-1-propyl-pyrrolidine-2,5-dione
  参考文献：
  名称：

  Kling, Chemische Berichte, 1897, vol. 30, p. 3041

  摘要：

  DOI：

文献信息

• [EN] TOPOSIOMERASE INHIBITORS<br/>[FR] INHIBITEURS DE TOPOISOMÉRASE
  申请人：UNIV RUTGERS

  公开号：WO2010127363A1

  公开（公告）日：2010-11-04

  The invention provides compounds of formula I: (I) wherein A, B, W, Y, Z, R1 R3 and R4 have any of the meanings defined in the specification and their salts as well as additional compounds and their salts. The invention also provides pharmaceutical compositions comprising a compound of the invention, processes for preparing compounds of the invention, intermediates useful for preparing compounds of the invention, and therapeutic methods for treating cancer, a bacterial infection or a fungal infection using compounds of the invention.

  该发明提供了以下公式I的化合物：(I)，其中A、B、W、Y、Z、R1、R3和R4具有规范中定义的任意含义及其盐，以及其他化合物及其盐。该发明还提供了包含该发明化合物的药物组合物，制备该发明化合物的方法，用于制备该发明化合物的有用中间体，以及使用该发明化合物治疗癌症、细菌感染或真菌感染的治疗方法。
• C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses
  申请人：Canadian Blood Services

  公开号：US20140369992A1

  公开（公告）日：2014-12-18

  The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.

  本公开提供了一种C端连接的氨基酸，用于调节凝血蛋白的溶栓、纤溶和/或抗凝血性能。本公开还提供了一种凝血蛋白，其催化位点被修饰，无论是在组氨酸或丝氨酸残基上，使用C端连接的氨基酸，以及这些修饰后的凝血蛋白的治疗应用。
• [EN] LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] CONJUGUÉS LIPIDIQUES POUR L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUES
  申请人：ARROWHEAD PHARMACEUTICALS INC

  公开号：WO2022056273A1

  公开（公告）日：2022-03-17

  Disclosed herein are compounds according to Formula (I) comprising PK/PD modulators for delivery of oligonucleotide-based agents, e.g., double stranded RNAi agents, to certain cell types, such for example skeletal muscle cells, in vivo. The PK/PD modulators disclosed herein, when conjugated to an oligonucleotide-based therapeutic or diagnostic agent, such as an RNAi agent, can enhance the delivery of the composition to the specified cells being targeted to facilitate the inhibition of gene expression in those cells.

  本文公开了公式（I）中的化合物，包括PK/PD调节剂，用于将基于寡核苷酸的制剂（例如双链RNAi制剂）递送到体内某些细胞类型，例如骨骼肌细胞。本文所披露的PK/PD调节剂与基于寡核苷酸的治疗或诊断制剂（如RNAi制剂）结合后，可以增强将该组合物递送到特定的目标细胞，以促进在这些细胞中抑制基因表达。
• REVERSIBLE PEGYLATED DRUGS
  申请人：SHECHTER Yoram

  公开号：US20100041867A1

  公开（公告）日：2010-02-18

  Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

  可逆的聚乙二醇化药物是通过将所选药物中的自由官能团（氨基、羟基、巯基、磷酸酯和/或羧基）衍生化为对弱碱性条件敏感的基团（例如9-芴甲氧羰基（Fmoc）或2-磺酸基-9-芴甲氧羰基（FMS）），然后将PEG基团连接到该基团上而得到的。在这些聚乙二醇化药物中，PEG基团和药物残基并非直接连接在一起，而是两个残基连接在高度敏感于碱性条件并可在生理条件下去除的Fmoc或FMS结构的不同位置上。这些药物最好是含有氨基团的药物，尤其是低分子量或中分子量的肽和蛋白质。类似的分子也可以用蛋白质载体或其他聚合物载体代替PEG基团。
• C-terminally tethered amino acids and their fibrinolytic therapeutic uses
  申请人：Canadian Blood Services

  公开号：EP2813567A1

  公开（公告）日：2014-12-17

  The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.

  本公开提供了一种用于调节凝血蛋白的溶栓、溶纤和/或抗凝特性的C-末端系链氨基酸。本公开还提供了一种凝血蛋白，其催化位点在组氨酸或丝氨酸残基处被 C-末端拴系氨基酸修饰，以及这些修饰凝血蛋白的治疗应用。